References
1. Low N., Chersich M.F., Schmidlin K., et al. Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. PLoS Med. 2011; 8: e1000416.
2. Atashili J., Poole C., Ndumbe P.M., Adimora A.A., Smith J.S. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS. 2008; 22: 1493–501.
3. Ravel J., Gajer P., Abdo Z., et al. Vaginal microbiome of reproductive- age women. Proc Natl Acad Sci USA. 2011; 108 (suppl 1): 4680–87.
4. McKinnon L.R., Achilles S.L., Bradshaw C.S., et al. The evolving facets of bacterial vaginosis: implications for HIV transmission. AIDS Res Hum Retroviruses. 2019; 35: 219–28.
5. Nold C., Anton L., Brown A., Elovitz M. Inflammation promotes a cytokine response and disrupts the cervical epithelial barrier: a possible mechanism of premature cervical remodeling and preterm birth. Am J Obstet Gynecol. 2012; 206: 208.e1–7.
6. Anton L., Sierra L.J., DeVine A., et al. Common cervicovaginal microbial supernatants alter cervical epithelial function: mechanisms by which Lactobacillus crispatus contributes to cervical health. Front Microbiol. 2018; 9: 2181.
7. Gosmann C., Anahtar M.N., Handley S.A., et al. Lactobacillus-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African women. Immunity. 2017; 46: 29–37.
8. Arnold K.B., Burgener A., Birse K., et al. Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIV-susceptible target cells. Mucosal Immunol. 2016; 9: 194–205.
9. Masson L., Passmore J.A.S., Liebenberg L.J., et al. Genital inflammation and the risk of HIV acquisition in women. Clin Infect Dis. 2015; 61: 260–69.
10. Masson L., Mlisana K., Little F., et al. Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study. Sex Transm Infect. 2014; 90: 580–7.
11. Joag V., Obila O., Gajer P., et al. Impact of standard bacterial vaginosis treatment on the genital microbiota, immune milieu, and ex vivo human immunodeficiency virus susceptibility. Clin Infect Dis. 2019; 68: 1675–83.
12. McClelland R.S., Lingappa J.R., Srinivasan S., et al. Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study. Lancet Infect Dis. 2018; 18: 554–64.
13. Srinivasan S., Richardson B.A., Wallis J., et al. Vaginal microbiota and HIV acquisition risk among African women. In: Conference on Retroviruses and Opportunistic Infections. Boston, MA, March 4–7, 2018: Abstr 268.
14. Anahtar M.N., Byrne E.H., Doherty K.E., et al. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity. 2015; 42: 965–76.
15. Ojala T., Kankainen M., Castro J., et al. Comparative genomics of Lactobacillus crispatus suggests novel mechanisms for the competitive exclusion of Gardnerella vaginalis. BMC Genomics. 2014; 15: 1070.
16. Bradshaw C.S., Morton A.N., Hocking J., et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006; 193: 1478–86.
17. Yang S., Reid G., Challis J.R.G., et al. Effect of oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 on the vaginal microbiota, cytokines and chemokines in pregnant women. Nutrients. 2020; 12: 368.
18. Happel A.U., Singh R., Mitchev N., et al. Testing the regulatory framework in South Africa – a single-blind randomized pilot trial of commercial probiotic supplementation to standard therapy in women with bacterial vaginosis. BMC Infect. Dis. 2020; 20: 491.
19. Bisanz J.E., Seney S., McMillan A., et al. A systems biology approach investigating the effect of probiotics on the vaginal microbiome and host responses in a double blind, placebo-controlled clinical trial of post-menopausal women. PLoS One. 2014; 9: e104511.
20. Cohen C.R., Wierzbicki M.R., French A.L., et al. Randomized trial of LACTIN-V to prevent recurrence of bacterial vaginosis. N Engl J Med. 2020; 382: 1906– 15.
21. Mohammadi A., Bagherichimeh S., Perry M.C., et al. The impact of cervical cytobrush sampling on cervico-vaginal immune parameters and microbiota relevant to HIV susceptibility. Sci Rep. 2020; 10: 8514.
22. Baron R.M., Kenny D.A. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986; 51: 1173–82.
23. Sabo M.C., Lehman D.A., Pintye J.C., et al. Elevation of cervical C-X-C motif chemokine ligand 10 levels is associated with HIV-1 acquisition in pregnant and postpartum women. AIDS. 2020; 34: 1725–33.
24. Wang Z., He Y., Zheng Y. Probiotics for the treatment of bacterial vaginosis: a meta-analysis. Int J Environ Res Public Health. 2019; 16: e3859.
25. Shannon B., Gajer P., Yi T.J., et al. Distinct effects of the cervicovaginal microbiota and herpes simplex type 2 infection on female genital tract immunology. J Infect Dis. 2017; 215: 1366–75.
26. Gajer P., Brotman R.M., Bai G., et al. Temporal dynamics of the human vaginal microbiota. Sci Transl Med. 2012; 4: 132ra52.
27. Happel A.U., Kullin B., Gamieldien H., et al. Exploring potential of vaginal Lactobacillus isolates from South African women for enhancing treatment for bacterial vaginosis. PLoS Pathog. 2020; 16: e1008559.
28. Hearps A.C., Tyssen D., Srbinovski D., et al. Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition. Mucosal Immunol. 2017; 10: 1480–90.
29. Delgado-Diaz D.J., Tyssen D., Hayward J.A., Gugasyan R., Hearps A.C., Tachedjian G. Distinct immune responses elicited from cervicovaginal epithelial cells by lactic acid and short chain fatty acids associated with optimal and non-optimal vaginal microbiota. Front Cell Infect Microbiol. 2020; 9: 446.
30. Kreisel K.M., Spicknall I.H., Gargano J.W., et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2018. Sex Transm Dis. 2021; 48: 208–14.